Table 5.

Multivariate analyses of risk factors for overall mortality among patients who were alive and disease free at one year after HCT

	number	RR	Odds Ratio		p-value
Presence of cGVHD
No cGVHD	3936	1.00
cGVHD	3547	1.56	1.41	1.73	<0.0001
Acute GVHD History					<0.0001
none	4051	1.00
aGVHD in first 29 days	2446	1.11	0.93	1.24	0.0716
aGVHD after day 29	986	1.46	1.28	1.67	<0.0001
Disease					<0.0001
AML	2541	1.00
ALL	1798	1.26	1.10	1.45	0.0008
CML	2498	0.73	0.64	0.83	<0.0001
MDS	652	0.84	0.70	1.00	0.0521
Disease Status at HCT					<0.0001
Early	4661	1.00
Intermediate	1823	1.25	1.10	1.41	<0.0001
Advanced	999	1.83	1.59	2.11	0.0005
HLA match					0.0191
Sibling Donor	1861	1.00
Well Matched Unrelated	1412	1.18	1.03	1.36	0.0199
Partially matched Unrelated	1369	1.12	0.92	1.29	0.1148
Poorly matched Unrelated	841	1.26	1.07	1.49	0.0049
TBI in the conditioning regimen
no	3186	1.00
yes	4292	1.20	1.07	1.34	0.0015
Sex match					<0.0001
Donor male/recipient male	2662	1.00
Donor male/recipient female	1720	0.94	0.83	1.08	0.3982
Donor female/recipient male	1629	1.43	1.27	1.62	<0.0001
Donor female/recipient female	1472	1.03	0.90	1.18	0.7114
Graft Source
Bone marrow	5354	1.00
Mobilized blood stem cells	2129	1.24	1.10	1.40	0.0004

Factors tested, but not listed in table: Recipient age, sex, donor parity, donor-recipient CMV serology, use of ATG, GVHD prophylaxis, aGVHD grade, year of transplant, platelet count at cGVHD diagnosis, serum bilirubin at cGVHD diagnosis, type of cGVHD onset, KPS/L at cGVHD diagnosis, severity of cGVHD at 1 year post-transplant, organ involvement of cGVHD at 1 year post-transplant